Whalesbook
AstraZeneca aur GSK, dono ki Q1 earnings ne sabko chaukane wala performance dikhaya hai, analyst ke predictions se bhi zyada numbers aaye hain. Yeh sab unke powerful drug portfolios ki wajah se ho paya.
AstraZeneca ki baat karein toh, unka EPS $2.58 raha, jo expectations se zyada tha. Iska main credit jata hai unke cancer drugs ki zabardast demand ko. CEO Pascal Soriot ka oncology mein leader banne ka strategy kaafi successful dikh raha hai.
Imfinzi aur Enhertu jaise blockbuster drugs ki sales mein 34% aur 30% ka growth dekha gaya hai Q1 2026 mein. Company ne apna full-year 2026 guidance bhi confirm kiya hai, jisme mid-to-high single-digit revenue growth aur low double-digit core EPS growth ka target hai. Unka bada ambition hai 2030 tak $80 billion revenue achieve karne ka. Q1 mein total revenue $15.3 billion raha, jo constant exchange rates par 8% zyada hai. Oncology aur rare diseases mein double-digit growth mili.
Ab GSK ki taraf dekhte hain. GSK ne bhi Q1 profits expectations se upar rakhe hain. Unka adjusted EPS 46.5 pence ($0.63) raha, jo 43.2 pence ke forecast se behtar hai. Yeh success unke specialized treatments ki wajah se hai jo HIV, cancer, aur immunology mein kaam aate hain.
CEO Luke Miels ke leadership mein GSK ek major transformation se guzar raha hai aur innovation par zyada focus hai. Miels ke aane ke baad se GSK ka stock nearly 34% badha hai. Company ka market cap approx $110.69 billion hai aur P/E ratio 14.74 hai, jo AstraZeneca ke 31.5 se kaafi kam hai.
GSK ne apna quarterly dividend bhi $0.4856 tak badhaya hai. Haalanki, analysts abhi bhi thoda cautious hain, jiska consensus rating "Reduce" aur average target price $53.00 hai. Iska reason unki pipeline aur diversification efforts par scrutiny hai.
Sector ki baat karein toh, pharma segment ne YoY 10.3% ka gain kiya hai. AstraZeneca ka higher P/E (31.5) uske aggressive growth targets ko dikhata hai, jabki GSK ka P/E (14.74) valuation ke hisaab se attractive lagta hai, par analysts ki chintaayein hain.
GSK shares earnings ke baad 1.6% tak increase hote hain, aur AstraZeneca ka stock year-to-date 2% aur pichle 12 mahino mein 34% badha hai.
Ab risks dekhte hain. AstraZeneca ka $80 billion ka target oncology pipeline par bahut depend karta hai, jaise Imfinzi aur Enhertu. Agar koi setback aaya toh growth affect ho sakti hai. Aur uska high P/E (31.5) future growth already priced in hone ka risk dikhata hai.
GSK ke liye challenge hai strategy ko sustain karna aur revenue streams ko diversify karna, kyunki key HIV medications ka impact future mein kam ho sakta hai. Analysts rating "Reduce" aur target $53.00 isi wajah se hai. GSK ka debt-to-equity ratio 0.92 aur current ratio 0.82 hai.
Aage dekhte hue, AstraZeneca ne full-year guidance confirm kiya hai, aur analyst rating "Moderate Buy" hai jiska average target $222.00 hai. GSK ka outlook divided hai, consensus "Reduce" aur target $53.00 hai, jo dikhata hai ki turnaround promise karta hai par hurdles abhi bhi hain.